§ 520.1350  
(11) Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[40 FR 13838, Mar. 27, 1975, as amended at 52 FR 7832, Mar. 13, 1987]

§ 520.1350 Meloxicam.  
(a) Specifications. Each milliliter of suspension contains 0.5 or 1.5 milligrams (mg) meloxicam.  
(b) Sponsor. See No. 000010 in §510.600(c) of this chapter for uses as in paragraph (c) of this section.  
(c) Conditions of use in dogs—(1) Amount. Administer orally as a single dose at 0.09 mg per pound (mg/lb) body weight (0.2 mg per kilogram (mg/kg)) on the first day of treatment. For all treatment after day 1, administer 0.045 mg/lb (0.1 mg/kg) body weight once daily.  
(2) Indications for use. For the control of pain and inflammation associated with osteoarthritis.  
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
[40 FR 13838, Mar. 27, 1975, as amended at 52 FR 7832, Mar. 13, 1987]

§ 520.1372 Methimazole.  
(a) Specifications. Each tablet contains 2.5 or 5 milligrams (mg) methimazole.  
(b) Sponsor. See No. 043264 in §510.600 of this chapter.  
(c) Conditions of use in cats—(1) Amount. The starting dose is 2.5 mg every 12 hours. Following 3 weeks of treatment, the dose should be titrated to effect based on individual serum total T4 levels and clinical response.  
(2) Indications for use. For the treatment of hyperthyroidism.  
(3) Limitations. Federal law restricts this drug to use by or on the order of a licensed veterinarian.  

§ 520.1380 Methocarbamol tablets.  
(a) Chemical name. 3-(O-Methoxyphenoxy)-1,2-propanediol 1-carbamate.  
(b) Specifications. Each tablet contains 500 milligrams of methocarbamol.  
(c) Sponsor. See No. 000856 in §510.600(c) of this chapter.  
(d) Conditions of use. (1) The drug is administered to dogs and cats as an adjunct to therapy for acute inflammatory and traumatic conditions of the skeletal muscles in order to reduce muscular spasms.  
(2) Dosage is based upon severity of symptoms and response noted. The usual initial dose in 60 milligrams per pound of body weight in two or three equally divided doses followed by 30 to 60 milligrams per pound of body weight each following day, usually not to exceed 14 to 21 days.  
(3) For use only by or on the order of a licensed veterinarian.
[40 FR 13838, Mar. 27, 1975, as amended at 67 FR 67521, Nov. 6, 2002]

§ 520.1408 Methylprednisolone tablets.  
(a) Specifications. Each tablet contains 1, 2, or 4 milligrams of methylprednisolone.  
(b) Sponsor. See No. 000009 in §510.600(c) of this chapter for use of 1- and 2-milligram tablets; see No. 000010 for use of 1- and 2-milligram tablets.  
(c) NAS/NRC status. The conditions of use have been NAS/NRC reviewed and found effective. NADA’s for approval of drugs for these conditions of use need not include effectiveness data specified by §514.111 of this chapter, but may require bioequivalency and safety information.  
(d) Special consideration. (1) Clinical and experimental data have demonstrated that corticosteroids administered orally or parenterally to animals may induce the first stage of parturition when administered during the last trimester of pregnancy and may precipitate premature parturition followed by dystocia, fetal death, retained placenta, and metritis.  
(2) Systemic therapy with methylprednisolone is contraindicated in animals with arrested tuberculosis, peptic ulcer, acute psychoses, or cushingoid syndrome. The presence of active tuberculosis, diabetes, osteoporosis, chronic psychotic reactions, predisposition to thrombophlebitis, hypertension, congestive heart failure, or renal insufficiency necessitates carefully controlled use of corticosteroids. Some of these conditions occur only rarely in